Jeffrey Kent, MD, an internal medicine specialist, has joined biopharmaceutical company Sling Therapeutics as its new chief medical officer, effective immediately.
Sling is in the late stages of developing an oral treatment for thyroid eye disease, and Dr. Kent will lead medical, clinical and regulatory functions for its newest phase 2 clinical trial.
Dr. Kent has over 20 years of experience with clinical development and medical affairs, most recently working as the executive vice president of medical affairs and outcomes research at Horizon Therapeutics.
"I am excited to be joining Sling and look forward to working with the outstanding leadership team here in progressing the company's late-stage clinical trial in TED, with the goal of delivering a safe, effective and convenient treatment option to patients," Dr. Kent said in a Jan. 25 press release.